HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The Characteristics of 206 Long-Term Survivors with Peritoneal Metastases from Colorectal Cancer Treated with Curative Intent Surgery: A Multi-Center Cohort from PSOGI.

AbstractBACKGROUND:
We conducted this study to review the patient characteristics associated with long-term survival in patients with peritoneal metastases from colorectal cancer who underwent cytoreductive surgery (CRS).
METHODS:
We retrospectively investigated patients with peritoneal metastases from CRC treated with curative intent surgery with or without hyperthermic intraperitoneal chemotherapy at 13 institutions worldwide between January 1985 and April 2015 and survived longer than five years after the first CRS for peritoneal metastases. Clinical and oncological features and therapeutic parameters were described and analyzed.
RESULTS:
Two hundred six long-term survivors were available for study. The median peritoneal cancer index (PCI) of this cohort was 4 (interquartile range (IQR), 2-7), and the median score of the small bowel regions of the PCI (SB-PCI) was 0 (IQR, 0-2). Complete cytoreduction (CC-0) was achieved in 180 (87.4%) patients. Recurrence was observed in 122 (59.2%) patients at a median of 1.8 (IQR, 1.2-2.6) years.
CONCLUSIONS:
While most long-term survivors showed low PCI/SB-PCI and CCR-0, some had characteristics considered associated with poor prognosis. Curative intent treatments may be considered in well-informed and fit patients showing negative factors affecting survival outcome.
AuthorsYasuyuki Kamada, Koya Hida, Yutaka Yonemura, Paul H Sugarbaker, Shadin Ghabra, Soichiro Ishihara, Hiroshi Nagata, Koji Murono, Takanori Goi, Kanji Katayama, Mitsuhiro Morikawa, Beate Rau, Pompiliu Piso, Miklos Acs, Federico Coccolini, Emel Canbay, Mao-Chih Hsieh, Aditi Bhatt, Pierre-Emmanuel Bonnot, Olivier Glehen
JournalCancers (Cancers (Basel)) Vol. 13 Issue 12 (Jun 13 2021) ISSN: 2072-6694 [Print] Switzerland
PMID34199234 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: